Ocuphire Pharma Investor Updates

P 18 2nd Endpoint: % of Subjects ≥ 15 Letter Gain In Near & ≤ 5 Letter Loss In Distance Phase 3 Approval Endpoint Also Showed Early Onset Of Near Vision Gain Without Loss of Distance Statistics Compared to Nyxol+LDP arm Powered for comparison to placebo whereas comparison to component arms were designed to inform the Phase 3 sample size 70% Percent of Subjects (%) 60% 50% 40% 30% 20% 10% 0% p=<0.0001 14% 61% p=0.03 33% 0.5 VEGA-1 Phase 2 Trial Percent of Subjects with 15 Letter Improvement in DCNVA and ≤ 5 Letter Loss in BCDVA Binocular p=0.008 26% Placebo (n=43) p=0.004 28% 61% Time Nyxol+LDP (n=43) 1 p=0.01 30% p=0.2 42% (Hours) Nyxol (n=30) p=<0.0001 14% LDP (n=31) 63% p=0.0009 20% 2 p=0.06 39% Source: VEGA-1 TLR Table 14.2.2.2 Percent of Subjects with >= 15 Letters of Improvement in Photopic DCNVA and < 5 Letters of Loss in Photopic Binocular BCDVA by Time Point (PP Population) Ocuphire PHARMA

View entire presentation